Humacyte (NASDAQ:HUMA) Price Target Cut to $1.00 by Analysts at TD Cowen

Humacyte (NASDAQ:HUMA) had its price target cut by stock analysts at TD Cowen from $3.50 to $1.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s target price indicates a potential upside of 48.02% from the company’s current price.

Several other research firms have also recently issued reports on HUMA. BTIG Research dropped their price target on Humacyte from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Friday. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Finally, UBS Group restated a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Humacyte has an average rating of “Moderate Buy” and an average target price of $7.36.

Humacyte Stock Performance

HUMA stock opened at $0.68 on Monday. The company has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $1.28. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $126.52 million, a P/E ratio of -3.38 and a beta of 1.89. Humacyte has a fifty-two week low of $0.67 and a fifty-two week high of $2.93.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Friday, March 27th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). Humacyte had a negative return on equity of 808.20% and a negative net margin of 1,998.87%.The firm had revenue of $0.47 million for the quarter, compared to analysts’ expectations of $1.35 million. Sell-side analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Institutional Trading of Humacyte

A number of institutional investors have recently added to or reduced their stakes in HUMA. R Squared Ltd bought a new position in Humacyte in the 4th quarter worth $25,000. Atom Investors LP acquired a new stake in shares of Humacyte in the fourth quarter valued at about $25,000. Truist Financial Corp bought a new position in shares of Humacyte in the third quarter worth about $28,000. Prudential Financial Inc. bought a new position in shares of Humacyte in the second quarter worth about $28,000. Finally, Financial Advisors Network Inc. bought a new stake in Humacyte during the 2nd quarter valued at approximately $28,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.